MENLO PARK, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients with chronic or debilitating disease, today announced that Paul B. Cleveland, president and chief executive officer of Avalanche, will present at two upcoming investor conferences:
- Cowen and Company’s 36th Annual Health Care Conference on Wednesday, March 9 at 9:20 a.m. ET in Boston, and
- Alliance for Regenerative Medicine’s 4th Annual Cell and Gene Therapy Investor Day on Tuesday, March 22 at 4:50 p.m. ET in New York.
A recorded webcast of Mr. Cleveland’s presentation at the Cowen and Company conference will be made available for replay under the Investors section of Avalanche’s website at www.avalanchebiotech.com.
About Avalanche Biotechnologies, Inc.
Avalanche is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients suffering from chronic or debilitating disease. Avalanche is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. With significant capabilities and expertise in vector optimization, process development and manufacturing, Avalanche seeks to discover and develop targets in ophthalmology and beyond.
Contacts Lauren Glaser, Head of Investor Relations (650) 656-9347 email@example.com